Sio Gene: Up after starting high-dose part of gene therapy study

Sio Gene Therapies

02/12/2020 18:28

** Drug developer's shares  SIOX.O  up 13.4% at $2.63, their
highest in more than a month
    ** Co says first patient in the high-dose cohort of its
early-to-mid-stage study has been treated with AXO-AAV-GM1, its
experimental gene therapy for Type I and Type II GM1
gangliosidosis  urn:newsml:reuters.com:*:nGNX3bPp1T
    ** GM1 gangliosidosis is an inherited disorder that
progressively destroys nerve cells in the brain and spinal cord
    ** Co expects to report topline data from the low-dose
cohort before year-end
    ** AXO-AAV-GM1 has received both "orphan drug" designation
and "rare pediatric disease" designation from the U.S. FDA (https://bit.ly/3mz5q43)
    ** Up to Tuesday's close, stock down 54.7% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))